Day: May 18, 2022

New technology and capacity help CDMO’s advanced-therapies campus meet growing market demand

SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA. These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings – enabling AGC Biologics to provide an in-depth variety of end-to-end cell and gene therapy services at this site.

North America has historically been home to more advanced therapy and regenerative medicine developers than any other region worldwide. Further, the 2021 Q3 Cell & Gene Therapies Market Outlook report from industry standard research (ISR) revealed viral vectors are the most common thing a drug developer needs from a CDMO. This expansion more than doubles the site’s viral vector capacity, and helps AGC Biologics meet these market demands.

“This investment helps AGC Biologics address the needs of gene therapy developers at our new central location in North America,” said Patricio Massera, CEO of AGC Biologics. “When you combine these new capabilities and the technical expertise at our Longmont campus, with our Milan facility’s lentiviral vector platform and its extensive gene therapy CDMO experience, we can now support virtually any viral vector program being developed anywhere in the world.”

The viral vector suspension expansion is a part of a more than $30 million investment by AGC Biologics in its new Longmont campus. The new suspension capabilities include a full complement of bioreactor sizes for product development (AMBR, 10L and 50L), and a complete range of commercial manufacturing capacities (50L, 200L, 500L and 2000L), enabling the site to provide support for the entire lifecycle of a product.

“The suspension expansion helps us offer the most impactful, efficient and scalable technologies for bringing viral vector-based gene therapy products to market,” said Tony Fraij, General Manager, AGC Biologics Longmont. “This latest investment helps us round out the services we offer at this campus. Now, with a full suite of capabilities and the extensive expertise of our scientists, we can support virtually any type of viral vector or cell therapy development and manufacturing project.”

AGC Biologics acquired the Longmont campus in August of 2021 and quickly appointed Fraij, a 20-year veteran with experience leading operations at several global life science organizations. The company previously acquired a cell and gene therapy site in Milan, Italy from MolMed S.p.A.  in 2020. The AGC Biologics Milan team’s technical expertise will play an important informative role in launching the new viral vector capabilities in Longmont. In just a few short years the company built a strong global cell and gene therapy network of services, capabilities and scientists. AGC Biologics is one of only a few CDMOs with end-to-end cell advanced therapies on two continents.

To learn more about the companies viral vector services visit www.agcbio.com/capabilities/viral-vector; visit www.agcbio.com/capabilities/cell-therapy to learn more about AGC Biologics’ cell therapy offerings.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

Attachments

• AGC Biologics Longmont Cell and Gene Therapy Campus
• AGC Biologics Longmont Cell and Gene Therapy Campus Aerial View

Nick McDonald
AGC Biologics
4254193555
nmcdonald@agc.com

London, May 17, 2022

CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that its wholly owned subsidiary, CNH Industrial Capital LLC, has priced $500 million in aggregate principal amount of 3.950% notes due 2025, with an issue price of 99.469%. The offering is expected to close on May 23, 2022, subject to the satisfaction of customary closing conditions.

CNH Industrial Capital LLC intends to add the net proceeds from the offering to its general funds and use them for working capital and other general corporate purposes, including, among other things, the purchase of receivables or other assets in the ordinary course of business. The net proceeds may also be applied to repay CNH Industrial Capital LLC’s indebtedness as it becomes due.

The notes, which are senior unsecured obligations of CNH Industrial Capital LLC, will pay interest semi-annually on May 23 and November 23 of each year, beginning on November 23, 2022, and will be guaranteed by CNH Industrial Capital America LLC and New Holland Credit Company, LLC, each a wholly owned subsidiary of CNH Industrial Capital LLC. The notes will mature on May 23, 2025.

Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and SG Americas Securities, LLC are acting as joint book-running managers and the representatives of the underwriters for the offering, and BBVA Securities Inc., Intesa Sanpaolo S.p.A., Natixis Securities Americas and UniCredit Capital Markets LLC are acting as joint book-running managers for the offering. The offering is being made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission on March 14, 2022. Copies of the prospectus supplement and the accompanying prospectus for the offering may be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-800-831-9146, Email: prospectus@citi.com; Deutsche Bank Securities Inc., 1 Columbus Circle, New York, NY 10019, Attn: Prospectus Group, Telephone: 1-800-503-4611, Email: prospectus.CPDG@db.com; Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, Telephone: 1-866-471-2526, Email: prospectus-ny@ny.email.gs.com; or SG Americas Securities, LLC, 245 Park Avenue, New York, NY 10167, Telephone: 1-855-881-2108. Copies of the prospectus supplement and the accompanying prospectus for the offering are also available on the website of the U.S. Securities and Exchange Commission at http://www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

CNH Industrial Capital LLC is an indirect wholly owned subsidiary of CNH Industrial N.V. and is headquartered in Racine, Wisconsin. As a captive finance company, the primary business of CNH Industrial Capital LLC and its subsidiaries is to underwrite and manage financing products for end-use customers and dealers of CNH Industrial America LLC and CNH Industrial Canada Ltd. (collectively, “CNH Industrial North America”) and provide other related financial products and services to support the sale of agricultural and construction equipment sold by CNH Industrial North America. CNH Industrial Capital LLC and its subsidiaries also provide wholesale and retail financing related to new and used agricultural and construction equipment manufactured by entities other than CNH Industrial North America. CNH Industrial Capital LLC’s principal executive offices are located at 5729 Washington Avenue, Racine, WI 53406, and the telephone number is +1(262) 636-6011.

Contacts:

Media Relations

 Email: mediarelations@cnhind.com

Investor Relations

 Email: investor.relations@cnhind.com

Attachment

• PR_pricing of CNHi Capital LLC $500 million notes FINAL

Web 3.0 Share-to-Earn online reviews marketplace, Tested Web, receives a $1,000,000 grant from the leading Blockchain-powered validation provider Silent Notary to empower consumers and businesses with authentic online reviews and insights.

AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) — Tested Web, a Web3.0 Online Reviews and Intelligence marketplace, announced its partnership today with Silent Notary, a blockchain-powered online validation and notarization provider. Through this partnership, Silent Notary will validate user-generated online reviews on the Tested Web platform, in addition to the latter’s L2 Solana-powered main protocol. Tested Web also becomes the first company to receive a $1,000,000 UBSN grant.

Established in 2018, Silent Notary is a multiplatform blockchain solution that ensures the existence, integrity, and attribution of communications, processes, and data that are critical to individuals and businesses. The solution certifies and protects user data without relying upon third parties.

Commenting on the collaboration, Max Breus, CEO of Dubai-based Silent Notary said, “Our collaboration with Tested Web strengthens our ability to offer an enhanced content validation experience for consumers around the world, as well as introduce Silent Notary to new markets. We’re excited to combine the Share-to-Earn vision of the Tested Web team with Silent Notary’s advanced decentralized validation solution. Consumers and businesses around the world will have peace of mind, and trust what they read – powered by this partnership. We are also excited to announce a $1,000,000 native UBSN grant to be used for content validations on Tested Web.”

Tested Web, based in Austin, was founded in 2021 after the founder, Yagub Rahimov, began exploring ways of democratizing the online reviews industry when a popular review platform inexplicably deleted his genuine review.

Tested Web will empower users with individual blockchain content wallets giving content ownership rights, smart-contract-powered community moderation, and a share-to-earn mechanism that rewards them for their contributions. The platform also provides businesses with unbiased real-time intelligence, insights, customer retention, and lead generation opportunities notwithstanding their marketing budgets.

Rahimov also quoted “We envision a transparent, real-trustworthy online reviews industry, that is severely lacking today. Our web3 vision involves an empowered hybrid DAO marketplace where users own their reviews, vote for moderation, and earn rewards based on their input. Decentralized validation is an essential part of this vision. Unfortunately, there is no one-size-fits-all among today’s blockchain solutions. While we’ve built the majority of our smart contracts, and operations as an L2 Solana protocol, we found Silent Notary’s solution to validate any content exceptionally fast and cost-effective. Even our early-stage operations require the capability to support 100,000+ blockchain validations every day, and via this partnership, we will be able to offer real-time and cost-effective validation to our community with complete transparency.”

Visit www.TestedWeb.com to learn more and join the limited whitelist.

Visit www.SilentNotary.com to learn more about Silent Notary and try the app.

Contact:

(Oscar) Min Khant Thaw

TestedWeb.com

twitter.com/testedweb

Related Images

Image 1: Silent Notary and Tested Web partnership

Web3 Online Reviews Marketplace Tested Web Announces Partnership With Silent Notary

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Silent Notary and Tested Web partnership